2-(羧甲基)-4-甲氧基苯甲酸 | 68294-03-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(羧甲基)-4-甲氧基苯甲酸
• 英文名称: 2-(carboxymethyl)-4-methoxybenzoic acid
• CAS: 68294-03-1
• 化学式: C₁₀H₁₀O₅
• 分子量: 210.186
• InChiKey: BOLRXRKAHDAYHL-UHFFFAOYSA-N

物化性质

• 熔点：
  222 °C
• 沸点：
  409.4±30.0 °C(Predicted)
• 密度：
  1.370±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  83.8
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 海关编码：
  2918990090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-(Carboxymethyl)-4-methoxybenzoic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-(Carboxymethyl)-4-methoxybenzoic acid
CAS number: 68294-03-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H10O5
Molecular weight: 210.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(羧甲基)-4-甲氧基苯甲酸 在 palladium on activated charcoal 吡啶 、 N-溴代丁二酰亚胺(NBS) 、 正丁基锂 、 碘苯二乙酸 、 氢气 、 三溴化硼 、 potassium carbonate 、 lithium tert-butoxide 作用下， 以 四氢呋喃 、 甲醇 、 四氯化碳 、 乙醚 、 二氯甲烷 、 乙酸乙酯 、 丙酮 为溶剂， 反应 24.0h， 生成 3-Bromomethyl-1,5,5,7,8,12-hexamethoxy-5H-benzo[a]anthracen-6-one
  参考文献：
  名称：

  Total Synthesis of (±)-O-Methyl PD 116740

  摘要：

  Condensation of the phthalide sulfide with an ortho-quinone monoketal was employed as a key step in the first total synthesis of a derivative of (+/-)-PD 116740.

  DOI：

  10.1021/ol026104r
• 作为产物：
  描述：

  5-methoxy-indan-1,2-dione 2-oxime 在 sodium hydroxide 、 对甲苯磺酰氯 作用下， 反应 1.0h， 以93%的产率得到2-(羧甲基)-4-甲氧基苯甲酸
  参考文献：
  名称：

  Reduced Benzimidazo[2,1-a]isoquinolines. Synthesis and Cytotoxicity Studies

  摘要：

  6-丁基-5,6-二氢苯并咪唑并[2,1-a]异喹啉、 3,9-和 3,10-二甲氧基、3,9-和 3,10-二羟基类似物及其 及其 12-甲基季铵盐的多步制备方法。细胞毒性 对 55 种人类癌细胞系的细胞毒性进行了测定。 研究所的筛选结果。二甲氧基化合物的季盐（15b/c） 二甲氧基化合物的季化合物盐（15b/c）显然最具活性，其平均图中点值（MGM 为 2 m。

  DOI：

  10.1071/ch01114

文献信息

• Sulfones as Synthetic Linchpins: Transition‐Metal‐Free sp ³ –sp ² and sp ² –sp ² Cross‐Couplings Between Geminal Bis(sulfones) and Organolithium Compounds
  作者：Barry M. Trost、Christopher A. Kalnmals

  DOI：10.1002/chem.201800118

  日期：2018.6.26

  carbon of the bis(phenylsulfonyl)methyl unit to ultimately generate trisubstituted alkenes, comprising formal sp3–sp2 and sp2–sp2 cross‐couplings between organolithium reagents and bis(sulfones). This process occurs almost instantaneously at −78 °C in the absence of any transition metals. By developing this curious transformation, it has been demonstrated that bis(phenylsulfonyl)methane is a valuable

  据报道，一种有价值的抗药性策略突出了双（苯磺酰基）甲基合成子的歧义性质，并证明了其作为合成的关键物质的效用。尽管通常将双（苯磺酰基）甲基作为sp 3碳亲核试剂引入，但事实证明，在有机锂亲核试剂存在下，它也可以作为有效的sp 2碳亲电试剂起作用。烷基锂和芳基锂与双（苯磺酰基）甲基单元的中心碳偶合，最终生成三取代的烯烃，包括形式为sp 3 –sp 2和sp 2 –sp 2的烯烃。有机锂试剂和双（砜）之间的交叉偶联。在没有任何过渡金属的情况下，该过程几乎在-78°C下瞬间发生。通过发展这种奇怪的转变，已证明双（苯磺酰基）甲烷是一种有价值的合成链节，它可以经历两个CC键形成过程，即一个sp 3-亲核体，然后进行第三次CC键形成。反应作为有效的sp 2-亲电子试剂。此发现显着增强了这个普遍存在但未充分利用的链接器组的实用性。
• Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof
  申请人：Tsou Hwei-Ru

  公开号：US20080085890A1

  公开（公告）日：2008-04-10

  This invention provides compounds of Formula (I), having the structure where G 1 , G 2 , G 3 , G 4 , A 1 , A 2 , Y 1 , Y 2 , L 1 , Z, e and f are defined herein, or a pharmaceutically acceptable salt thereof, which are useful for treating or preventing cancer.

  这项发明提供了具有结构的化合物（I），其中G1、G2、G3、G4、A1、A2、Y1、Y2、L1、Z、e和f在此处定义，或其药用可接受盐，用于治疗或预防癌症。
• [EN] 1-ARYL-4-SUBSTITUTED ISOQUINOLINES<br/>[FR] ISOQUINOLINES 1-ARYL-4-SUBSTITUEES
  申请人：NEUROGEN CORP

  公开号：WO2005110991A1

  公开（公告）日：2005-11-24

  1-Aryl-4-substituted isoquinolines analogues of Formula (I) and Formula (II) are provided, as follows : wherein R1, R2, R3, R8, R9, A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula (I) and (II) bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to pharmaceutical compositions compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled 1-aryl-4-substituted isoquinolines, which are useful as probes for the localization of C5a receptors.

  提供了Formula (I)和Formula (II)的1-芳基-4-取代异喹啉类似物，具体如下：其中R1、R2、R3、R8、R9、A和Ar在此处定义。这些化合物是C5a受体的配体。Formula (I)和(II)的优选化合物与C5a受体结合亲和力高，并在C5a受体上表现为中性拮抗剂或逆向激动剂活性。本发明还涉及包含这些化合物的药物组合物，以及利用这些化合物治疗各种炎症、心血管和免疫系统疾病的用途。此外，本发明提供了标记的1-芳基-4-取代异喹啉，可用作C5a受体的定位探针。
• INDENOISOQUINOLINONE DERIVATIVES, MANUFACTURING METHOD AND MEDICAL USE THEREOF
  申请人：Xiang Hua

  公开号：US20130085140A1

  公开（公告）日：2013-04-04

  Indenoisoquinolinone derivatives (I), the manufacturing method and the medical use thereof, which belong to pharmaceutical chemistry and organic chemistry field, are disclosed. These compounds can be used for treating several medical symptoms related to postmenopausal syndrome, uterine fibers deterioration and aortic smooth muscle cells proliferation, especially ER-(+) depend breast cancer. Meanwhile, these compounds can also be used for treating glioma and lung cancer, and have inhibiting effect on tumor metastasis effect on tumor metastasis.

  本发明涉及Indenoisoquinolinone衍生物(I)的制备方法和医药用途，属于制药化学和有机化学领域。这些化合物可用于治疗与绝经后综合征、子宫纤维退化和主要是ER-(+)依赖性乳腺癌相关的多种医疗症状。同时，这些化合物还可用于治疗胶质瘤和肺癌，并对肿瘤转移具有抑制作用。
• INHIBITORS OF CATHEPSIN B
  申请人：Holsinger Leslie

  公开号：US20090203629A1

  公开（公告）日：2009-08-13

  The present invention is directed to a method of using compounds of Formula (I) to inhibit Cathepsin B. Specifically the compounds of the present invention are useful as therapeutic agents for the treatment of tumor invasion, metastasis, Alzheimer's Disease, arthritis, inflammatory diseases such as chronic and acute pancreatitis, inflammatory airway disease, and bone and joint disorders, including osteoporosis, osteoarthritis, rheumatoid arthritis, psoriasis, and other autoimmune disorders, liver fibrosis, including liver fibrosis associated with HCV, all types of steatosis (including non-alcoholic steatohepatitis) and alcohol-associated steatohepatitis, non-alcoholic fatty liver disease, forms of pulmonary fibrosis including idiopathic pulmonary fibrosis, pathological diagnosis of interstitial pneumonia following lung biopsy, renal fibrosis, cardiac fibrosis, retinal angiogenesis and fibrosis/gliosis in the eye, schleroderma, and systemic sclerosis. The compounds of Formula (I) are also useful for treating subjects with both HCV and fibrosis in a mammal, particularly liver fibrosis, and subjects affirmatively diagnosed or at risk for both HCV and liver fibrosis.

  本发明涉及一种使用化合物I的方法来抑制蛋白酶B。具体地说，本发明的化合物可用作治疗肿瘤侵袭、转移、阿尔茨海默病、关节炎、慢性和急性胰腺炎、炎症性疾病（如慢性和急性胰腺炎、炎症性气道疾病、骨骼和关节疾病，包括骨质疏松症、骨关节炎、类风湿性关节炎、牛皮癣和其他自身免疫性疾病、包括与丙型肝炎病毒相关的肝纤维化、所有类型的脂肪变性（包括非酒精性脂肪肝炎）和酒精相关性脂肪肝炎、非酒精性脂肪肝病、包括特发性肺纤维化、肺活检后的间质性肺炎病理诊断、肾脏纤维化、心脏纤维化、视网膜血管生成和眼部纤维化/胶质增生、硬皮病和全身性硬化症等疾病的治疗剂。化合物I也适用于治疗哺乳动物中同时患有丙型肝炎病毒和纤维化的受试者，特别是肝纤维化，以及已经确诊或有患有丙型肝炎病毒和肝纤维化风险的受试者。